03.1A Psychopharmacology

160
1 Medical Students

description

Psychopharmacology presentation

Transcript of 03.1A Psychopharmacology

Page 1: 03.1A Psychopharmacology

1

Medical Students

Page 2: 03.1A Psychopharmacology

2

Hierarchy of Conditions

Page 3: 03.1A Psychopharmacology

3

Role of drugs

Typical Antipsychotics

• Thought to act by blocking specific brain receptors

• e.g. mesolimbic D2 receptors

Receptor blockade takes hours yet clinical effect takes weeks. Homovalinic acid levels takes weeks to fall

Page 4: 03.1A Psychopharmacology

4

Generally act by blocking dopamine receptors in particular D2. Can give rise to S/E’s

Also can affect cholinergic, alpha adrenergic, histamine and serotonin receptors.

Page 5: 03.1A Psychopharmacology

5

Possible Pathways

Involved

4 Dopamine Lines:

- Brainstem to Limbic System – Too much Dopamine is thought to be cause for POSITIVE symptoms

- Brainstem to Mesocortical System – Too little dopamine is thought to be cause for NEGATIVE symptoms

- Brainstem to Basal Ganglia – Blocking Dopamine causes movement disorders

- Brainstem to Hypothalamus – Blocking Dopamine leads to Hyperprolactinaemia

Page 6: 03.1A Psychopharmacology

6

Relative Times to achieve maximal

effects of antipsychotic drugs

Page 7: 03.1A Psychopharmacology

7

Acute Episodes

Drug induced – illicit or prescription?

Pharmacological management is necessary

Informed choice

First line – atypical monotherapy within BNF limits, particularly if the patient cannot give informed consent

Atypicals – if experiencing EPSEs, otherwise continue with regular treatment

Advance Directives

Acute cases respond better than chronic patients

May require additional sedatives.

Page 8: 03.1A Psychopharmacology

8

1st

Episode Schizophrenia

Start agreed antipsychotic

Titrate if necessary

1st onset of antipsychotic action – 2/52

Assess at optimum dosage over 4-6 weeks

If successful, continue.

1-2 years treatment. Probably needed longer.

If not, change antipsychotic

If not successful, consider clozapine

Page 9: 03.1A Psychopharmacology

9

Acute Exacerbation

• Continue/restart usual treatment

May consider a short term sedative

Avoid increasing antipsychotic dose

May switch to another antipsychotic if appropriate

If ineffective, switch to clozapine

Page 10: 03.1A Psychopharmacology

10

Why do patients get acute

exacerbations?

Page 11: 03.1A Psychopharmacology

11

Little proven advantage of using high doses or polypharmacy in most clinical situations.

Royal College Statement. Consensus statement on high dose antipsychotic medication.

Majority of the response likely within 3-4 weeks.

If no response by 6 - 8 weeks then raising doses further usually of little benefit.

Early treatment associated with better prognosis.

High Dose Antipsychotic

Medication

Page 12: 03.1A Psychopharmacology

12

If no response review

symptoms e.g.

Affective symptoms? Concurrent mood stabiliser?

Depressive symptoms? Concurrent antidepressant?

Side effects e.g. akathisia.

Acceptability of side effects.

Compliance.

Page 13: 03.1A Psychopharmacology

13

Relapse

Occurs in 80% of untreated cases.

20% who would not relapse cannot be identified.

Maintenance therapy significantly reduces relapse rate.

If treatment stopped, relapse may be delayed.

The patient may feel better before relapse.

Page 14: 03.1A Psychopharmacology

14

Typicals divided into:

Low potency (e.g. chlorpromazine 1952)

Less extrapyramidal side effects (EPSE’s)

more sedative

increased postural hypotension

increased anticholinergic side effects

eg chlorpromazine and thioridazine.

High potency (e.g. haloperidol 1958)

the reverse

eg haloperidol and trifluoperazine.

Page 15: 03.1A Psychopharmacology

15

Class of Antipsychotics

Phenothiazines –Chlorpromazine, promazine, pipothiazine, fluphenazine, trifluoperazine

Butyrophenones – Haloperidol -potent D2 blocker, high level of EPSE. Depot formulation

Thioxanthenes – Flupenthixol and zuclopenthixol – mainly used as depots

Diphenylbutylpiperidines – pimozide – fairly dopamine specific. ECGs if dose higher than 16mg/day

Page 16: 03.1A Psychopharmacology

16

Class of Antipsychotic

Sulpiride

-doses <800mg per day- main affinity is for pre-synaptic D4 receptors -less inhibition of dopamine release & more dopamine available at the synapse. ↑doses, D2 affinity dominates resulting in

post synaptic blockade of D2 receptors

Page 17: 03.1A Psychopharmacology

17

Extrapyramidal Side Effects

Page 18: 03.1A Psychopharmacology

18

EPSE-Dystonia

Sustained involuntary muscle contractions.

Twisting of neck, limbs,trunk or face.

Acute form more likely in younger, more ill patients.

Especially antipsychotic naïve, with predominant negative symptoms.

Can occur after a few doses or several years.

Page 19: 03.1A Psychopharmacology

19

Treatment of Choice

Switch to an atypical or an atypical with less risk of EPSEs

Parenteral anticholinergic e.g. procyclidine IM or IV in acute situations

Page 20: 03.1A Psychopharmacology

20

Dystonic Reaction

This 29 year old women was the product of a normal, full-term pregnancy and a vaginal breech birth. She developed fairly normally until the sixth grade, when she was found to require special education classes. IQ testing revealed a score of 37.

She stopped school at grade 9. At age 20, she had episodic violent behavior, for which she took haloperidol for 5 years and risperidone for 3 years.

One year before evaluation, she had involuntary pulling of the neck backward, and tardive dystonia was diagnosed.

She obtained partial relief from oral trihexiphenidyl, baclofen, clonazepam, and tetrabenazine, in combination with botulinum toxin injections.

She has severe cervical and oral dystonia.

Page 21: 03.1A Psychopharmacology

21

EPSE-Parkinsonian

Akinesia.

Rigidity.

Course tremor at rest but no pill rolling.

May occur within weeks.

Remit on withdrawal of drug.

Page 22: 03.1A Psychopharmacology

22

Treatment

Switch to an atypical or an atypical with less risk of EPSE.

If not an option, consider as required procyclidine (oral).

Page 23: 03.1A Psychopharmacology

23

EPSE-Akathisia.

Uncontrolled restlessness with feelings of inability to keep still.

Constantly shifting posture, rocking pacing the floor.

May resemble agitation or psychosis.

Use validated rating scale to assess such as Barnes Akathisia Rating Scale.

Page 24: 03.1A Psychopharmacology

24

Treatment

Switch to an atypical or an atypical with less risk of EPSE.

If not an option, consider propranolol.

Procycline is less efficacious.

Page 25: 03.1A Psychopharmacology

25

EPSE-Tardive Dyskinesia (TD)

Involuntary hyperkinesia. increases with anxiety,and relieved with sleep.

May be irreversible.

Symptoms include tics, choreas and dystonias.

Repetitive, involuntary, purposeless movements of : jaw, neck and tongue.

Page 26: 03.1A Psychopharmacology

26

Treatment

Switch to an atypical or an atypical with less risk of EPSE.

If necessary consider:

Tetrabenzine (licensed) or

Vitamin E liquid (not licensed) or

Clonazepam (not licensed).

Page 27: 03.1A Psychopharmacology

27

Antimuscarinics

Benzatropine mesilate

Orphenadrine hydrochloride

Procyclidine hydrochloride

Trihexyphenidyl hydrochloride (Benzhexol)

Page 28: 03.1A Psychopharmacology

28

Antimuscarinic Side

Effects

Dry mouth

Blurred vision

GI disturbance e.g. constipation

Urinary retention

Tachycardia

Mental confusion

Contra-indicated in untreated urinary retention, glaucoma, GI obstruction

Page 29: 03.1A Psychopharmacology

29

Is it a good idea to give patients antimuscarinics/anticholinergics regularly?

Page 30: 03.1A Psychopharmacology

30

Neuroleptic Malignant

Syndrome

Inc. Rigidity, fever, confusion, fluctuating BP, tachycardia.

Elevated creatine kinase.

? Dopamine deficiency.

Risk factors inc. – high potency drugs, rapid dose changes, agitation, dehydration, abrupt withdrawal of anticholinergics, concurrent lithium.

Page 31: 03.1A Psychopharmacology

31

Treatment

Life threatening. Withdraw antipsychotic immediately. Monitor TPR. May need to be admitted to A&E. Rehydrate, artificial ventilation. Sedate with benzodiazepines. Dantrolene – muscle relaxant. Bromocriptine – dopamine agonist. ECT for psychosis.

Page 32: 03.1A Psychopharmacology

32

Subsequent treatment of

Psychosis

No antipsychotics for at least 5 days.

Wait for symptoms to resolve inc. CPK.

Use small doses of an unrelated antipsychotic, preferably not a long acting one and one with low dopamine affinity.

Monitor for symptoms of NMS –TPR, CPK.

Page 33: 03.1A Psychopharmacology

33

Psychotropic Related QT

prolongation

Some antipsychotics block cardiac potassium channels and are linked to the cardiac QT prolongation which is a risk factor for ventricular arrhythmias.

Some are assoc. with an extremely low risk of sudden death.

Risk factors – cardiac, low K, Ca & Mg, stress, physical exertion , anorexia nervosa.

Particularly relevant in RT and with high doses.

Page 34: 03.1A Psychopharmacology

34

Other Side Effects

Hyperprolactinaemia.

Drowsiness.

Postural hypotension.

Weight gain.

Anticholinergic side effects.

Increased glucose levels.

Page 35: 03.1A Psychopharmacology

35

What medical checks could

you do as safety precautions?

Page 36: 03.1A Psychopharmacology

36

Atypical antipsychotics available in

United Kingdom

Atypical Neuroleptics

Clozapine Olanzapine Zotepine Aripripazole Amisulpride Risperidone Quetiapine

Page 37: 03.1A Psychopharmacology

37

Atypical antipsychotics.

Better tolerated than Typicals ?

EPSE’s and prolactin elevation less frequent.

Efficacy in negative symptoms.

Care in patients with cardiovascular disease, epilepsy or Parkinson's.

S/E’s- weight gain, dizziness, postural hypotension, EPSE’s (mild and transient, respond to dose reduction), NMS rarely, Occasionally TD.

Page 38: 03.1A Psychopharmacology

38

Pharmacology of clozapine

Clozapine discovered 1966.

Indicated for treatment resistance. Considered more effective in all aspects of schizophrenia.

Effective in 30-50% treatment resistant cases. May reach 60% if adequate dosing for 12 weeks.

Delaying treatment until after an extended period with typical/ other

atypicals may reduce eventual effectiveness of clozapine

Page 39: 03.1A Psychopharmacology

39

Can cause reversible Neutopenia (3%). Can progress to agranulocytosis (0.8%).

Not dose related. Risk higher in elderly and those with lower baseline wbc counts.

Onset 8-10 weeks.

Treatment restricted by blood tests:

weekly (for 18 weeks).

Fortnightly (for 52 weeks).

monthly ever after.

Page 40: 03.1A Psychopharmacology

40

Clozapine

Interactions inc.

Carbamazepine and various medicines which cause neutropenia are contraindicated.

Fluovoxamine in particular may increase clozapine levels.

Smoking.

Page 41: 03.1A Psychopharmacology

41

Clozapine – Side Effects

inc.

Sore throat , fever -

Hypersalivation – must be treated.

Constipation – must be treated.

Seizures – must be treated.

Urinary incontinence.

Drowsiness.

Hypotension.

Page 42: 03.1A Psychopharmacology

42

Clozapine – Side Effects inc.

Tachycardia – investigate and treat if necessary.

Weight gain – potential long term problems.

Raised glucose and cholesterol levels.

Pulmonary embolism.

Myocarditis.

Cardiomyopathy.

Page 43: 03.1A Psychopharmacology

43

If Clozapine on it’s own does

not work – augmentation with

A second antipsychotic.

Fish oils – deficiency in fatty acids in cell membranes.

Lamotrigine – reduces release of glutamate.

Check clozapine levels – interpretation.

Page 44: 03.1A Psychopharmacology

44

Are all atypical

antipsychotics equivalent?

Page 45: 03.1A Psychopharmacology

45

Alternative Strategies for

TRS

Little evidence base:

High dose olanzapine (30-60mg per day).

High dose quetiapine.

Omega – 3- Triglycerides augmentation.

Page 46: 03.1A Psychopharmacology

46

Depot Antipsychotics

Haloperidol decanoate

Pipotiazine palmitate

Fluphenazine decanaote

Flupentixol decanoate

Zuclopenthixol decanoate

Risperidone long acting injection (atypical)

Paliperidone depot

Olanzapine pamoate depot (atypical)

Page 47: 03.1A Psychopharmacology

47

Depot Antipsychotics

Slow onset of action – several weeks

10-12 weeks to steady state.

Removal from the body also takes a long time – several weeks.

Concurrent oral antipsychotics.

Olanzapine depot – e-learning programme due to low incidence of sedation, confusion, disorientation, convulsions.

Page 48: 03.1A Psychopharmacology

48

Advantages AND Disadvantages

of depot medication

Page 49: 03.1A Psychopharmacology

49

Physical Health Checks

Weight gain.

Diabetes.

Hyperprolactinaemia.

Cardiovascular risk factors.

Side effects of medication.

Lifestyle factors – smoking.

Cannabis.

Page 50: 03.1A Psychopharmacology

50

How and When to Stop

Treatment

Risk Benefit Analysis.

Abrupt withdrawal is more likely to lead to a relapse within the first six months.

Careful surveillance.

Page 51: 03.1A Psychopharmacology

51

What the Patient needs to

Know

Antipsychotics do not cure schizophrenia.

Long term treatment is required to prevent relapses.

Side effects should be discussed.

Antipsychotics should not be stopped suddenly.

Page 52: 03.1A Psychopharmacology

52

Page 53: 03.1A Psychopharmacology

Rapid Tranquillisation

and

Benzodiazepines

Audrey Coker

Camden and Islington

Mental Health Foundation

Trust

Page 54: 03.1A Psychopharmacology

What is RT?

• Rapid tranquillisation has a limited evidence

base because clinical trials are difficult to

conduct.

• It is a pharmacological strategy used to

manage a high risk of imminent violence.

• Tranquillisation means calming without

sedating.

Page 55: 03.1A Psychopharmacology

The Dilemma ….

• The aim of RT is not to treat any underlying illness or disorder.

• This must proceed alongside RT, but is distinct from RT.

• Violence need not be associated with psychosis for RT to be an appropriate therapy.

• Violence that is associated with psychosis may respond to non-pharmacological intervention.

Page 56: 03.1A Psychopharmacology

The Aim

• To manage an agitated,

irritable, hostile or

violent episode.

• To calm the patient so

they can be safely

managed and be safe to

others.

• To alleviate disturbing symptoms.

• Providing the lowest

side effect load.

• Using the lowest,

most effective dose.

• Being cost-effective.

Page 57: 03.1A Psychopharmacology

What drugs do we use?

ANTIPSYCHOTIC

• Traditionally

Haloperidol

• Atypical

Antipsychotics

may be used and

may be better

tolerated

BENZODIAZEPINES

• Used as better

tolerated

COMBINATION

• Some evidence that

this works

synergistically

• Also can mean

giving less of more

toxic

antipsychotics

Page 58: 03.1A Psychopharmacology

Routes

• Always offer tablets, syrup or

fast dissolving tablets first

• The IM route should only be

used if the patient will not

accept oral medication or has

not responded to it – lorazepam,

haloperidol, aripiprazole

Page 59: 03.1A Psychopharmacology

• Would you give all patients a

combination of an antipsychotic

and a benzodiazepine?

Page 60: 03.1A Psychopharmacology

SIDE EFFECTS

• Acute dystonia

• Hypotension

• Neuroleptic

Malignant Syndrome (NMS)

• Arrhythmias

• Respiratory depression

Page 61: 03.1A Psychopharmacology

• What would you do if a patient

had a history of NMS or dystonia

to haloperidol?

Page 62: 03.1A Psychopharmacology

Monitoring

Requirements

After IM medication

• Alertness

• Temperature

• Pulse

• Blood pressure

• Respiratory rate

• Continuous pulse oximetry

every 15 minutes for 2 hours

then

every 30 minutes until patient is

ambulatory

then

continue to monitor alertness,

mental state and behaviour

ECG Fluid balance & electrolyte balance

Page 63: 03.1A Psychopharmacology

Clopixol Acuphase

• Onset of action 2 hours

• Peak sedative action: 12 hours

• Lasts 72 hours

• May be increased minimum of every

24 hrs to a maximum of 4 injections

and 400mg in total in two weeks

• Monitoring vital signs over the

period.

Page 64: 03.1A Psychopharmacology

• Would you give someone

clopixol acuphase if he/she

experienced dystonia to

haloperidol?

Page 65: 03.1A Psychopharmacology

Adverse Effects of Long Term

Benzodiazepine Use:

• Drugs of abuse

• Tolerance

• Hangover effect

• Disinhibition

• Confusion

• Respiratory

Depression

Page 66: 03.1A Psychopharmacology

Be Firm!!

• Offer alternatives where available

• Be strict with TTA’s

• Be observant with regular use

• If long term use, withdrawal must be very

gradual

Page 67: 03.1A Psychopharmacology

Rapid Tranquillisation

and

Benzodiazepines

Audrey Coker

Camden and Islington

Mental Health Foundation

Trust

Page 68: 03.1A Psychopharmacology

What is RT?

• Rapid tranquillisation has a limited evidence

base because clinical trials are difficult to

conduct.

• It is a pharmacological strategy used to

manage a high risk of imminent violence.

• Tranquillisation means calming without

sedating.

Page 69: 03.1A Psychopharmacology

The Dilemma ….

• The aim of RT is not to treat any underlying illness or disorder.

• This must proceed alongside RT, but is distinct from RT.

• Violence need not be associated with psychosis for RT to be an appropriate therapy.

• Violence that is associated with psychosis may respond to non-pharmacological intervention.

Page 70: 03.1A Psychopharmacology

The Aim

• To manage an agitated,

irritable, hostile or

violent episode.

• To calm the patient so

they can be safely

managed and be safe to

others.

• To alleviate disturbing symptoms.

• Providing the lowest

side effect load.

• Using the lowest,

most effective dose.

• Being cost-effective.

Page 71: 03.1A Psychopharmacology

What drugs do we use?

ANTIPSYCHOTIC

• Traditionally

Haloperidol

• Atypical

Antipsychotics

may be used and

may be better

tolerated

BENZODIAZEPINES

• Used as better

tolerated

COMBINATION

• Some evidence that

this works

synergistically

• Also can mean

giving less of more

toxic

antipsychotics

Page 72: 03.1A Psychopharmacology

Routes

• Always offer tablets, syrup or

fast dissolving tablets first

• The IM route should only be

used if the patient will not

accept oral medication or has

not responded to it – lorazepam,

haloperidol, aripiprazole

Page 73: 03.1A Psychopharmacology

• Would you give all patients a

combination of an antipsychotic

and a benzodiazepine?

Page 74: 03.1A Psychopharmacology

SIDE EFFECTS

• Acute dystonia

• Hypotension

• Neuroleptic

Malignant Syndrome (NMS)

• Arrhythmias

• Respiratory depression

Page 75: 03.1A Psychopharmacology

• What would you do if a patient

had a history of NMS or dystonia

to haloperidol?

Page 76: 03.1A Psychopharmacology

Monitoring

Requirements

After IM medication

• Alertness

• Temperature

• Pulse

• Blood pressure

• Respiratory rate

• Continuous pulse oximetry

every 15 minutes for 2 hours

then

every 30 minutes until patient is

ambulatory

then

continue to monitor alertness,

mental state and behaviour

ECG Fluid balance & electrolyte balance

Page 77: 03.1A Psychopharmacology

Clopixol Acuphase

• Onset of action 2 hours

• Peak sedative action: 12 hours

• Lasts 72 hours

• May be increased minimum of every

24 hrs to a maximum of 4 injections

and 400mg in total in two weeks

• Monitoring vital signs over the

period.

Page 78: 03.1A Psychopharmacology

• Would you give someone

clopixol acuphase if he/she

experienced dystonia to

haloperidol?

Page 79: 03.1A Psychopharmacology

Adverse Effects of Long Term

Benzodiazepine Use:

• Drugs of abuse

• Tolerance

• Hangover effect

• Disinhibition

• Confusion

• Respiratory

Depression

Page 80: 03.1A Psychopharmacology

Be Firm!!

• Offer alternatives where available

• Be strict with TTA’s

• Be observant with regular use

• If long term use, withdrawal must be very

gradual

Page 81: 03.1A Psychopharmacology
Page 82: 03.1A Psychopharmacology

Bipolar Mood Disorders-

Medication

Audrey Coker

Senior Pharmacist Mental

Health Services

Camden and Islington

Mental Health Foundation

Trust

Page 83: 03.1A Psychopharmacology

Mood

Page 84: 03.1A Psychopharmacology

Acute Mania (No prior

medication)

Stop any antidepressant.

Consider an antipsychotic particularly if severe behavioural problems or

Valproate (avoid in women of child bearing age).

Lithium (if future adherence is likely)

Antipsychotic + valp. Or li.

Consider a short term benzodiazepine.

Page 85: 03.1A Psychopharmacology

Why should antidepressants

be stopped

Page 86: 03.1A Psychopharmacology

Why are antipsychotics used?

Page 87: 03.1A Psychopharmacology

Acute Mania – previous

antimanic medication

If taking an antipsychotic:-

Compliance.?

Increase dose if necessary. Consider adding lithium or valproate.

If taking lithium or valproate, check plasma levels. Increase dose to levels of up max. +/- antipsychotic.

Page 88: 03.1A Psychopharmacology

Acute Mania – previous

antimanic medication

Carbamazepine – consider adding an antipsychotic (higher doses may be needed).

Short term benzodiazepines may be added.

Page 89: 03.1A Psychopharmacology

If a patient presented in a depressive phase after a period of non compliance what could you prescribe?

Page 90: 03.1A Psychopharmacology

Mode of Action

Li+ may reduce higher intracellular conc. of Na and Ca, reduce activity of Na dependent I/C 20 messenger systems, protein kinase C? Neuroprotective via NMDA pathways? Modulate dopamine and serotonin pathways. Reduced turnover of arachidonic acid.

Carbamazepine blocks voltage dependent sodium channels, inhibiting repetitive neuronal firing, reduces glutamate release and the turnover of dopamine and noradrenaline.

Valproate inhibits the catabolism of GABA, reduced turnover of arachidonic acid, reduced levels of protein kinase C, inhibition of voltage gated Na channels, promote brain derived neurotrophic factor.

Page 91: 03.1A Psychopharmacology

Lithium

Generally 70-80% effective in aborting an acute manic or hypomanic episode.

Takes 7-14 days after starting therapy.

Prophylactic lithium therapy required in 70-80% to prevent recurrences of mania, hypomania or depression.

Adverse effects: Short Term

GI upset, Nausea, Polydipsia, Polyuria, Nocturia, dry mouth, fine hand tremor, leukocytosis, muscle weakness, difficulty concentrating, impaired memory,

Long Term

weight gain, altered taste, decreased libido, hypothyroidism, rash, acne, psoriasis, alopecia, non specific T wave changes, premature ventricular beats, nephrogenic diabetes insipidus, nephrotoxicity, fine hand tremor

Toxic > 1.5mmol/l

Severe drowsiness, coarse hand tremor, muscle twitching, myoclonus, cogwheel rigidity, vomiting, loss of appetite, ataxia, nystagmus, seizures, coma & death

Page 92: 03.1A Psychopharmacology

Lithium Preparations

Keep to same brand/ preparation because of bioavailability.

Write Rx in proprietary format (brand name).

Monitor more frequently when changing between brands & formulation.

Carbonate not equivalent to citrate

Page 93: 03.1A Psychopharmacology

Pre-lithium Work Up

ECG, TFTs, Us&Es inc. serum creatinine and urea.

Starting Dose: 400mg per day.

Elderly: 200mg per day.

Levels in 5-7 days 12 hours post dose

Range: 0.4 – 1.0mmol/l.

A salt free diet is contraindicated.

Page 94: 03.1A Psychopharmacology

Monitoring of patients on

Lithium

Lithium blood levels - every 3 months (patients on established treatment)

Blood sample at same time interval post dose (ideally 12-18 hours)

On a 6 monthly

basis the following should be checked: urea & electrolytes, renal function, thyroid function, weight, bp, pulse, ECG

Certain patients may require more frequent monitoring, eg elderly, those on interacting drugs, medical co morbidity such as renal, thyroid, cardiac disease.

Page 95: 03.1A Psychopharmacology

Changes in Lithium Levels

Situations that may increase plasma

lithium levels

Decreased sodium intake or increased sodium excretion

Low sodium diet

Diuretics, ACEIs, Angiotensin antagonists

Excessive exercise/sweating

Protracted diarrhoea/ vomiting

Salt deficiency

Decrease water intake or increased water excretion

Dehydration

Diuretics (thiazide and potassium sparing)

Fever

Physical illness (flu, surgery, diarrhoea, vomiting)

Postpartum fluid changes

Slimming diets

Renal disease or decreased renal blood flow

Renal dysfunction

Nonsteroidal anti-inflammatory agents

Page 96: 03.1A Psychopharmacology

Drug Interactions

Haloperidol or Carbamazepine – may cause neurotoxicity occasionally.

SSRIs may cause CNS toxicity.

Page 97: 03.1A Psychopharmacology

Stopping Lithium

Reduce slowly over at least a month, preferably 3 months even if another mood stabiliser is added.

Page 98: 03.1A Psychopharmacology

Carbamazepine &

Valproate

Carbamazapine Neurological adverse effects: dizziness, fatigue, ataxia,

blurred vision, nystagmus, dysarthria, confusion.

GI side effects Mild to severe rashes Agranulocytosis, aplastic

anaemia SIADH Liver enzymes elevation Neutropenia

DRUG INTERACTIONS!!

Valproate GI upset and sedation ataxia, lethargy, fine tremor,

alopecia, pruritus, prolonged bleeding, liver enzymes increase, weight gain, thrombocytopenia

Established teratogen – must discuss with women of child bearing age – folate

Page 99: 03.1A Psychopharmacology

Carbamazepine &

Valproate

Carbamazepine.

Autoinducer – low initial doses.

Check levels in 2-4 weeks.

Dose of at least 600mg per day and a serum level of 7mg/l (range: 4-12mg/l).

Valproate.

Level of 50-125mg/l.

Side effects are often dose related.

Page 100: 03.1A Psychopharmacology

Carbamazepine &

Valproate

Carbamazepine

Interactions

Antipsychotic

Antidepressants

Methadone

Benzodiazepines

Washout with MAOIs

C/I - clozapine

Valproate

Interactions

Warfarin – protein binding displacement

Increase levels of lamotrigine

Valproate levels increased by erythromin, fluoxetine

Page 101: 03.1A Psychopharmacology

Other Options

Lamotrigine – bipolar depression.

Clozapine – resistant bipolar illness (not licensed).

Page 102: 03.1A Psychopharmacology

Rapid Cycling BAD

Withdraw antidepressants.

Consider precipitants e.g. thyroid dysfunction.

Optimise mood stabilisers e.g. lithium + valproate.

If no response options with a smaller evidence base may be considered e.g. clozapine, lamotrigine, thyroxine.

Page 103: 03.1A Psychopharmacology

Prophylaxis

1st line – lithium, olanzapine and valproate

Rx for 2yrs or longer.

Antidepressants may be used on combn with an antimanic agent for acute depressive episodes.

Rapid cyclers – lithium + valproate.

Page 104: 03.1A Psychopharmacology

Bipolar Depression

Initial use of an SSRI + an anti manic agent.

Or Quetiapine (if not antipsychotic already prescribed).

Mirtazapine or venlafaxine may be used as the antidepressant.

Or add quetiapine, olanzapine or lithium to the antidepressant.

Page 105: 03.1A Psychopharmacology

Bipolar Mood Disorders-

Medication

Audrey Coker

Senior Pharmacist Mental

Health Services

Camden and Islington

Mental Health Foundation

Trust

Page 106: 03.1A Psychopharmacology

Mood

Page 107: 03.1A Psychopharmacology

Acute Mania (No prior

medication)

Stop any antidepressant.

Consider an antipsychotic particularly if severe behavioural problems or

Valproate (avoid in women of child bearing age).

Lithium (if future adherence is likely)

Antipsychotic + valp. Or li.

Consider a short term benzodiazepine.

Page 108: 03.1A Psychopharmacology

Why should antidepressants

be stopped

Page 109: 03.1A Psychopharmacology

Why are antipsychotics used?

Page 110: 03.1A Psychopharmacology

Acute Mania – previous

antimanic medication

If taking an antipsychotic:-

Compliance.?

Increase dose if necessary. Consider adding lithium or valproate.

If taking lithium or valproate, check plasma levels. Increase dose to levels of up max. +/- antipsychotic.

Page 111: 03.1A Psychopharmacology

Acute Mania – previous

antimanic medication

Carbamazepine – consider adding an antipsychotic (higher doses may be needed).

Short term benzodiazepines may be added.

Page 112: 03.1A Psychopharmacology

If a patient presented in a depressive phase after a period of non compliance what could you prescribe?

Page 113: 03.1A Psychopharmacology

Mode of Action

Li+ may reduce higher intracellular conc. of Na and Ca, reduce activity of Na dependent I/C 20 messenger systems, protein kinase C? Neuroprotective via NMDA pathways? Modulate dopamine and serotonin pathways. Reduced turnover of arachidonic acid.

Carbamazepine blocks voltage dependent sodium channels, inhibiting repetitive neuronal firing, reduces glutamate release and the turnover of dopamine and noradrenaline.

Valproate inhibits the catabolism of GABA, reduced turnover of arachidonic acid, reduced levels of protein kinase C, inhibition of voltage gated Na channels, promote brain derived neurotrophic factor.

Page 114: 03.1A Psychopharmacology

Lithium

Generally 70-80% effective in aborting an acute manic or hypomanic episode.

Takes 7-14 days after starting therapy.

Prophylactic lithium therapy required in 70-80% to prevent recurrences of mania, hypomania or depression.

Adverse effects: Short Term

GI upset, Nausea, Polydipsia, Polyuria, Nocturia, dry mouth, fine hand tremor, leukocytosis, muscle weakness, difficulty concentrating, impaired memory,

Long Term

weight gain, altered taste, decreased libido, hypothyroidism, rash, acne, psoriasis, alopecia, non specific T wave changes, premature ventricular beats, nephrogenic diabetes insipidus, nephrotoxicity, fine hand tremor

Toxic > 1.5mmol/l

Severe drowsiness, coarse hand tremor, muscle twitching, myoclonus, cogwheel rigidity, vomiting, loss of appetite, ataxia, nystagmus, seizures, coma & death

Page 115: 03.1A Psychopharmacology

Lithium Preparations

Keep to same brand/ preparation because of bioavailability.

Write Rx in proprietary format (brand name).

Monitor more frequently when changing between brands & formulation.

Carbonate not equivalent to citrate

Page 116: 03.1A Psychopharmacology

Pre-lithium Work Up

ECG, TFTs, Us&Es inc. serum creatinine and urea.

Starting Dose: 400mg per day.

Elderly: 200mg per day.

Levels in 5-7 days 12 hours post dose

Range: 0.4 – 1.0mmol/l.

A salt free diet is contraindicated.

Page 117: 03.1A Psychopharmacology

Monitoring of patients on

Lithium

Lithium blood levels - every 3 months (patients on established treatment)

Blood sample at same time interval post dose (ideally 12-18 hours)

On a 6 monthly

basis the following should be checked: urea & electrolytes, renal function, thyroid function, weight, bp, pulse, ECG

Certain patients may require more frequent monitoring, eg elderly, those on interacting drugs, medical co morbidity such as renal, thyroid, cardiac disease.

Page 118: 03.1A Psychopharmacology

Changes in Lithium Levels

Situations that may increase plasma

lithium levels

Decreased sodium intake or increased sodium excretion

Low sodium diet

Diuretics, ACEIs, Angiotensin antagonists

Excessive exercise/sweating

Protracted diarrhoea/ vomiting

Salt deficiency

Decrease water intake or increased water excretion

Dehydration

Diuretics (thiazide and potassium sparing)

Fever

Physical illness (flu, surgery, diarrhoea, vomiting)

Postpartum fluid changes

Slimming diets

Renal disease or decreased renal blood flow

Renal dysfunction

Nonsteroidal anti-inflammatory agents

Page 119: 03.1A Psychopharmacology

Drug Interactions

Haloperidol or Carbamazepine – may cause neurotoxicity occasionally.

SSRIs may cause CNS toxicity.

Page 120: 03.1A Psychopharmacology

Stopping Lithium

Reduce slowly over at least a month, preferably 3 months even if another mood stabiliser is added.

Page 121: 03.1A Psychopharmacology

Carbamazepine &

Valproate

Carbamazapine Neurological adverse effects: dizziness, fatigue, ataxia,

blurred vision, nystagmus, dysarthria, confusion.

GI side effects Mild to severe rashes Agranulocytosis, aplastic

anaemia SIADH Liver enzymes elevation Neutropenia

DRUG INTERACTIONS!!

Valproate GI upset and sedation ataxia, lethargy, fine tremor,

alopecia, pruritus, prolonged bleeding, liver enzymes increase, weight gain, thrombocytopenia

Established teratogen – must discuss with women of child bearing age – folate

Page 122: 03.1A Psychopharmacology

Carbamazepine &

Valproate

Carbamazepine.

Autoinducer – low initial doses.

Check levels in 2-4 weeks.

Dose of at least 600mg per day and a serum level of 7mg/l (range: 4-12mg/l).

Valproate.

Level of 50-125mg/l.

Side effects are often dose related.

Page 123: 03.1A Psychopharmacology

Carbamazepine &

Valproate

Carbamazepine

Interactions

Antipsychotic

Antidepressants

Methadone

Benzodiazepines

Washout with MAOIs

C/I - clozapine

Valproate

Interactions

Warfarin – protein binding displacement

Increase levels of lamotrigine

Valproate levels increased by erythromin, fluoxetine

Page 124: 03.1A Psychopharmacology

Other Options

Lamotrigine – bipolar depression.

Clozapine – resistant bipolar illness (not licensed).

Page 125: 03.1A Psychopharmacology

Rapid Cycling BAD

Withdraw antidepressants.

Consider precipitants e.g. thyroid dysfunction.

Optimise mood stabilisers e.g. lithium + valproate.

If no response options with a smaller evidence base may be considered e.g. clozapine, lamotrigine, thyroxine.

Page 126: 03.1A Psychopharmacology

Prophylaxis

1st line – lithium, olanzapine and valproate

Rx for 2yrs or longer.

Antidepressants may be used on combn with an antimanic agent for acute depressive episodes.

Rapid cyclers – lithium + valproate.

Page 127: 03.1A Psychopharmacology

Bipolar Depression

Initial use of an SSRI + an anti manic agent.

Or Quetiapine (if not antipsychotic already prescribed).

Mirtazapine or venlafaxine may be used as the antidepressant.

Or add quetiapine, olanzapine or lithium to the antidepressant.

Page 128: 03.1A Psychopharmacology
Page 129: 03.1A Psychopharmacology

129

Depression and its

Treatment

Audrey Coker

Senior Psychiatry Pharmacist

Page 130: 03.1A Psychopharmacology

130

Contents

Introduction

Causes

Principles of treatment

Choice of drug

Drugs used

Page 131: 03.1A Psychopharmacology

131

Abnormalities in monoamine

neurotransmission in depression

5-HT

Decreased plasma tryptophan

Blunted 5-HT neuroendocrine responses

Clinical relapse after tryptophan depletion

Noradrenaline

Blunted noradrenaline-mediated growth hormone release

Dopamine

Decreased homovanillic acid (HVA) levels in CSF

Page 132: 03.1A Psychopharmacology

132

Drugs which are depressogenic

Cardiovascular Drugs: -blockers, calcium channel blockers, digoxin, methyldopa, statins.

Hormones: corticosteroids, oestrogens, progestogens.

Drugs acting on CNS: alcohol, amphetamine (withdrawal), amantadine, benzodiazepines, carbamazepine, levodopa, phenothiazines.

Antibacterials: sulphonamides, ciprofloxacin.

Miscellaneous: disulfiram, interferon-, isotretinoin, mefloquine, metoclopramide, NSAIDs, -blockers.

Page 133: 03.1A Psychopharmacology

133

Role of Antidepressants

Virtually all available antidepressants are

equally effective if given at an adequate dose for a

sufficient time

Most cases resolve with time

Antidepressants hasten recovery and reduce suffering.

Indicated for a major depressive disorder that is moderate to severe.

Page 134: 03.1A Psychopharmacology

134

Principles of treatment

1) Eliminate contributory causes

e.g. other drugs, excessive caffeine intake, physical causes such as anaemia and hypothyroidism.

Page 135: 03.1A Psychopharmacology

135

Factors to consider when

choosing an antidepressant

Previous response to class of antidepressants. Tolerability and adverse effects of previous antidepressants. Effects of antidepressants on co-morbidity. Lethality in overdose. Concurrent physical illness or condition. Associated psychiatric disorder that may specifically respond to a

particular class of antidepressant. (eg, obsessive compulsive disorder and serotonin reuptake inhibitors) Patient preference.

Page 136: 03.1A Psychopharmacology

136

Principles of Treatment

Discuss with the patient, choice of drug and non pharmacological options.

Explain it does not work immediately.

Prescribe a dose of antidepressant likely to be effective.

Is episode continue for 4-6 moths after recovery.

Reduce slowly to reduce discontinuation rxns.

Page 137: 03.1A Psychopharmacology

137

Rx Options

1st line – SSRI assess over 4-6 weeks.

If successful – continue for 6 mths.

If not - ineffective/poorly tolerated - another antidepressant for 4-6 weeks.

If no effect – refractory Rx options.

No evidence that any antidepressant works faster.

Page 138: 03.1A Psychopharmacology

138

Duration of Treatment For

Major Depression

Age

<39

40-49

>50

1st episode 6-9 m 6-9 m Indef

2nd 6-9 m 4-5 y Indef

2nd + complication 4-5 y Indef Indef

Third or subsequent Indef Indef Indef

Page 139: 03.1A Psychopharmacology

139

Classes of antidepressants

TCAs and related compounds

Amitriptyline, amoxapine, clomipramine, desipramine, doxepin,

imipramine, nortriptyline, protriptyline, trazodone, lofepramine

MAOIs

Isocarboxazid, phenelzine, tranylcypromine

SSRIs

Citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline

Miscellaneous antidepressants

Venlafaxine, nefazodone, mirtazapine, reboxetine, moclobemide

Page 140: 03.1A Psychopharmacology

140

Selective Serotonin Reuptake

Inhibitors SSRI’s

Drugs of choice but for cost.

Low risk in overdose, safety in heart conditions, better s/e profile.

Cost more per day than TCA’s but may be cheaper in the long run.

e.g. fluoxetine, paroxetine, sertraline, citalopram.

Page 141: 03.1A Psychopharmacology

141

Side Effects of SSRIs

Insomnia.

Agitation.

Dystonia – paroxetine.

Increased risk of bleeding. This is additvie to that produced by aspirin and NSAIDs.

Sexual dysfunction.

Page 142: 03.1A Psychopharmacology

142

Mirtazapine

Often used as a second line agent after an SSRI.

Relatively safe in overdose, but not yet considered as safe SSRIs.

Drowsiness.

Weight gain.

Rare cases of neutropenia.

Page 143: 03.1A Psychopharmacology

143

Venlafaxine

Often used as a 2nd / 3rd line agent and also in patients acknowledged treatment resistant depression.

Care in patients with CVS problems.

↑BP at higher doses.

Not as safe as SSRIs, but not as dangerous as TCAs.

Page 144: 03.1A Psychopharmacology

144

Tricyclic antidepressants

TCA’s

Doses of 125-150mg/day effective.

No evidence supporting <75mg.

In community 88% of doses < accepted effective levels.

Older TCA’s high doses cause more s/e’s.

e.g. amitriptyline, clomipramine, dothiepin, lofepramine.

Dangerous in overdose.

Page 145: 03.1A Psychopharmacology

145

Side effects of TCAs

Anticholinergic side effects.

Arrhythmogenic properties.

Hypotension.

Drowsiness.

Sexual dysfunction.

Page 146: 03.1A Psychopharmacology

146

Monoamine Oxidase

Inhibitors

Hardly ever used.

Used for ‘atypical’ depression.

Patient has to be counselled about diet and over the counter medicines and prescribed medicines.

Also dangerous in overdose.

Page 147: 03.1A Psychopharmacology

147

Hyponatraemia

Most antidepressants cause this.

Risk factors – old age, female LBW, low baseline Na, concurrent medication, hypothyroidism, diabetes, warm weather.

May need to be clinically managed.

SSRIs are more likely to cause it.

Lofepramine, reboxetine and moclobemide are less likely. ECT.

Page 148: 03.1A Psychopharmacology

148

Withdrawal Syndrome

GI & somatic distress, sleep disturbances, movement disorders, hypomania.

Due to cholinergic / adrenergic overdrive.

Appears 1-14 days after cessation, lasts 7 – 14 days. Differs to relapse.

Treat with low doses, or leave to resolve and reassure.

ARE ANTIDEPRESSANTS ADDICTIVE?

Page 149: 03.1A Psychopharmacology

149

Serotonin Syndrome

May occur when two antidepressants are administered together.

May occur when crosstapering.

Other concurrent drugs may cause it e.g. tramadol.

Page 150: 03.1A Psychopharmacology

150

Serotonin Syndrome

Restlessness.

Tremor.

Shivering.

Myoclonus.

Confusion.

Convulsions.

Death.

Page 151: 03.1A Psychopharmacology

151

Cross Tapering

Guidelines in the Maudsley.

MAOIs – ‘cheese reaction’.

With monoamine oxidase inhibitors, wait for 2 weeks after stopping the MAOI before starting another.

If switching to an MAOI, the washout period depends on the T1/2 of the previous antidepressant.

Page 152: 03.1A Psychopharmacology

152

Resistant depression

30-80% of `treatment resistant’ cases are under treated.

50% of these respond to improved dosing.

True resistance:

treated with higher doses.

logical combinations.

Augmentation.

assuring compliance.

Page 153: 03.1A Psychopharmacology

153

Treatment Resistant

Depression

Venlafaxine inhibits serotonin reuptake at low doses and also noradrenaline at high doses. Supported by NICE.

ECT.

Lithium (low doses) added to an antidepressant.

SSRI + mirtazapine or mianserin (NICE).

Phenelzine – failure to respond to others.

Page 154: 03.1A Psychopharmacology

154

Resistant Depression

Add tri-iodothyronine – less popular, but now supported by STAR*D.

Add an antipsychotic to the antidepressant.

Psychotic depression – may require an antipsychotic as well. TCAs best evidence base as antidepressant.

Venlafaxine + mirtazapine (Maudsley Guide)

Others are less widely used either due to toxicity –MAOI and a TCA or poor evidence base – addition of tryptophan.

Page 155: 03.1A Psychopharmacology

155

Psychotic Depression

TCAs are probably more effective.

But response rate is poorer than in patients with non psychotic major depression.

A combn of an antipsychotic + an antidepressant is more effective than an antipsychotic alone.

ECT may be indicated.

Page 156: 03.1A Psychopharmacology

156

St John’s Wort

May be effective in mild to moderate depression only.

Active component not yet determined.

Uncertainty about therapeutic dose.

Page 157: 03.1A Psychopharmacology

157

St John’s Wort

S/Es – dry mouth, nausea, dizziness, photosensitivity.

May cause hypomania (like other antidepressants).

Reduces levels of e.g. CoCs, antiretrovirals and warfarin.

Page 158: 03.1A Psychopharmacology

158

Key Points Patients Should

Know

A single episode of depression should be treated for 6 months after recovery.

The risk of recurrence of depressive illness is high and increases with each episode.

Those with multiple episodes may require long term treatment.

Treatment doses are required.

Page 159: 03.1A Psychopharmacology

159

Key Points Patients Should

Know

Antidepressants are:

Effective.

Non addictive.

Not known to lose efficacy over time.

Not known to cause long term effects.

Medication should be reduced slowly under the supervision of a doctor.

Page 160: 03.1A Psychopharmacology

160

Summary

Depression is a common psychiatric illness especially in primary care.

Antidepressants hasten recovery and reduce suffering.

It is important to give them in adequate doses for adequate periods.

Care is needed when switching antidepressants.